1. |
吴立文. 难治性癫痫的诊断和治疗. 中华神经科杂志, 2002, 35(1): 55-57.
|
2. |
郭帅, 张冉冉, 刘学伍. 非离子类抗癫痫发作机制及相关药物研究进展. 中华神经科杂志, 2021, 54(6): 612-619.
|
3. |
Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurology, 2020, 77(3): 300-308.
|
4. |
Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of Fenfluramine for the treatment of seizures associated with Lennox-Gastaut Syndrome: a randomized clinical trial. JAMA Neurol. 2022, 79(6): 554-564.
|
5. |
Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, 2019, 394(10216): 2243-2254.
|
6. |
童馨, 慕洁. Dravet综合征——从癫痫性脑病到离子通道病. 癫痫杂志, 2016, 2(3): 264-269.
|
7. |
中国抗癫痫协会创新与转化专委会. Lennox-Gastaut综合征诊断治疗的中国专家共识. 癫痫杂志, 2022, 8(3): 187-195.
|
8. |
Auvin S. Lennox-Gastaut syndrome: new treatments and treatments under investigation. Rev Neurol (Paris), 2020, 176(6): 444-447.
|
9. |
Verrotti A, Striano P, Iapadre G, et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure, 2018, 63: 17-25.
|
10. |
Devinsky O, King L, Schwartz D, et al. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia, 2021, 62(7): e98-e102.
|
11. |
Balagura G, Cacciatore M, Grasso EA, et al. Fenfluramine for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs, 2020, 34(10): 1001-1007.
|
12. |
Strzelczyk A, Schubert-Bast S. A practical guide to the treatment of dravet syndrome with anti-seizure medication. CNS Drugs, 2022, 36(3): 217-237.
|
13. |
Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol, 2017, 8: 191.
|
14. |
Polster T. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome. Epilepsy Behav, 2019, 91: 99-102.
|
15. |
Steriade C, French J, Devinsky O. Epilepsy: key experimental therapeutics in early clinical development. Expert Opin Investig Drugs, 2020, 29(4): 373-383.
|
16. |
Johannessen Landmark C, Potschka H, Auvin S, et al. The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results. Epilepsia, 2021, 62(4): 857-873.
|
17. |
Martin P, Reeder T, Sourbron J, et al. An Emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci, 2021, 22(16): 8416.
|
18. |
Rodríguez-Muñoz M, Sánchez-Blázquez P, Garzón J. Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget, 2018, 9(34): 23373-23389.
|
19. |
谷珊珊, 卢洁. Sigma-1受体在缺血性脑卒中中的研究进展. 卒中与神经疾病, 2021, 28(1): 114-116.
|
20. |
Verrotti A, Striano P. Novel therapeutic options for Dravet and Lennox-Gastaut syndrome. Expert Rev Neurother, 2021, 21(11): 1191-1194.
|
21. |
Odi R, Invernizzi RW, Gallily T, et al. Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know. Pharmacol Ther, 2021, 226: 107866.
|
22. |
Lagae L, Schoonjans AS, Gammaitoni AR, et al. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome. Epilepsia, 2018, 59(10): 1881-1888.
|
23. |
Sharawat IK, Panda PK, Kasinathan A, et al. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: a systematic review and meta-analysis. Seizure, 2021, 85: 119-126.
|
24. |
Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for lennox-gastaut syndrome: current and future strategies. CNS Drugs, 2021, 35(1): 61-83.
|
25. |
Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla® ) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia, 2020, 61(11): 2396-2404.
|
26. |
Geenen KR, Doshi SP, Patel S, et al. Fenfluramine for seizures associated with Sunflower syndrome. Dev Med Child Neurol, 2021, 63(12): 1427-1432.
|
27. |
Lai WW, Galer BS, Wong PC, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia, 2020, 61(11): 2386-2395.
|
28. |
Silenieks LB, Carroll NK, Van Niekerk A, et al. Evaluation of selective 5-HT2C agonists in acute seizure models. ACS Chem Neurosci, 2019, 10(7): 3284-3295.
|
29. |
Simon K, Sheckley H, Anderson CL, et al. A review of fenfluramine for the treatment of Dravet syndrome patients. Curr Res Pharmacol Drug Discov, 2021, 3: 100078.
|
30. |
伍仁琴. 血清素综合征简介. 四川精神卫生, 2001, 16(3): 192-193.
|
31. |
Devinsky O, Hesdorffer DC, Thurman DJ, et al. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol, 2016, 15(10): 1075-1088.
|
32. |
Cross JH, Galer BS, Gil-Nagel A, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure, 2021, 93: 154-159.
|
33. |
Gil-Nagel A, Sullivan J, Ceulemans B, et al. Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy Behav, 2021, 122: 108212.
|
34. |
Vidaurre J, Herbst J. Nuevos fármacos antiepilépticos [New antiepileptic drugs]. Medicina (B Aires), 2019;79(Suppl 3): 48-53.
|